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Juvenile idiopathic arthritis (JIAs) is the most common chronic rheumatic disease of
childhood and is an important cause of disability. The folic acid analog methotrexate
is the first choice disease-modifying anti-rheumatic drug in this disease, however,
35–45% of patients fail to respond. Molecular elements, such as variants in genes
of pharmacological relevance, influencing response to methotrexate in JIA, would
be important to individualize treatment strategies. Several studies have evaluated
the effects of candidate genetic variants in the complex pathway of genes involved
in methotrexate pharmacodynamics and pharmacokinetics, however, results are still
contrasting and no definitive genetic marker of methotrexate response useful for the
clinician to tailor therapy of children with JIA has been identified. Recently, genome-
wide approaches have been applied, identifying new potential biological processes
involved in methotrexate response in JIA such as TGF-beta signaling and calcium
channels. If these genomic results are properly validated and integrated with innovative
analyses comprising deep sequencing, epigenetics, and pharmacokinetics, they will
greatly contribute to personalize therapy with methotrexate in children with JIA.
Keywords: juvenile idiopathic arthritis, methotrexate, pharmacogenomics, genome-wide association study, gene
expression profiling
Introduction: Juvenile Idiopathic Arthritis and Methotrexate
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood
and is an important cause of disability (Ravelli and Martini, 2007). A rapid control of inﬂam-
mation allows avoiding structural damage and growth impairment. Today there are lots of
treatment options, especially biologics targeting cytokines are continuously developing (Lovell
et al., 2000, 2008; Brunner et al., 2014). Among the conventional disease modifying anti-rheumatic
drugs (DMARDs), methotrexate remains ﬁrst-line therapy for children with JIA, due to long-
term eﬃcacy, safety proﬁle and low-cost (Giannini et al., 1992; Ramanan et al., 2003). It is
used as ﬁrst disease-modifying and steroid-sparing medication, but it is useful also in syner-
gism with biological drugs to prevent antibody formation (Lovell et al., 2008; Horneﬀ et al.,
2009).
Recent improvements in treatment and management of JIA have increased expectations from
clinicians, parents, and patients for complete and early control of disease. Pharmacological
determinants, including genetic markers, useful to predict treatment outcome, may be crucial
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to select the right drug for each patient, maximizing treatment
eﬃcacy, and reducing long-term complications of the disease
(Stocco et al., 2012). However, research is still ongoing to iden-
tify the appropriate markers for methotrexate and the other
DMARDs (Cobb et al., 2014; Schmeling et al., 2014).
The folic acid analog methotrexate is the ﬁrst choice DMARD
in JIA (Giannini et al., 1992; Becker, 2011), however, 35–45% of
patients fail to respond (Ruperto et al., 2004; Wallace et al., 2012).
Methotrexate determines its antiproliferative activity through
inhibition of several enzymatic pathways in which folates are
relevant, in particular by interfering with the activity of the
enzymes dihydrofolate reductase (DHFR) and thymidylate syn-
thetase (TYMS; Mikkelsen et al., 2011). However, the mechanism
of action of methotrexate in JIA is still under investigation, and its
anti-inﬂammatory eﬀects may be mediated by additional mecha-
nisms to folate antagonism (Chan and Cronstein, 2010). Indeed,
co-treatment with folic acid prevents toxic eﬀects of methotrex-
ate and not the therapeutic eﬀects in JIA (Morgan and Baggott,
2010; Schmeling et al., 2014). Additional mechanisms may
involve adenosine release, inhibition of spermine/spermidine
production and/or alteration of cellular redox state (Cronstein,
2005). In particular, the eﬃcacy of methotrexate in JIA has been
ascribed to the release of anti-inﬂammatory adenosine, through
inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide
formyltransferase (ATIC) and consequent accumulation of intra-
cellular purine nucleotides (Cronstein et al., 1991; Dervieux et al.,
2011; Figure 1).
Identiﬁcation of patients who are likely to respond to
methotrexate would be very important for the clinician. Clinical
improvement is indeed usually seen after 6–12 weeks of
methotrexate therapy. Given this time lag between methotrex-
ate treatment initiation and the patient response, it would be
particularly useful to determine a priori the probability of ther-
apeutic eﬃcacy: the delay in identifying the optimal treatment at
an early stage of disease can inﬂuence the long-term joint dam-
age. The use of fully validated pharmacogenomics markers may
allow to identify responsive patients that could be treated with
methotrexate (Schmeling et al., 2014). On the contrary, patients
with variants associated with lack of eﬃcacy for methotrexate
should be switched more rapidly to a more aggressive treatment
(for example methotrexate plus biologics; Pastore et al., 2014).
Early identiﬁcation of the right therapy could prevent defor-
mity and growth disturbance, with great beneﬁt for children
with JIA.
FIGURE 1 | Methotrexate pathway. Methotrexate and its active
polyglutamate metabolites interfere with several intracellular metabolic
processes in particular one-carbon metabolism and de novo purine and
pyrimidine synthesis, by inhibiting the activity of key enzymes such as DHFR,
ATIC, and TYMS. This antimetabolic effect may lead to alteration in intracellular
nucleotide pools and increased adenosine release, determining the
anti-rheumatic effect of methotrexate. ABCs, ATP-binding cassette transporters;
AMP, adenosine monophosphate; ATIC, adenosine ribonucleotide
transformylase; DHFR, dihydrofolate reductase; FPGS, folylpolyglutamate
synthase; GGH, gamma-glutamyl hydrolase; IMP, inosine monophosphate; ITP:
inosine triphosphate; ITPA, inosine triphosphate-pyrophosphatase; SLC19A1,
solute carrier family 19 member 1; TYMS, thymidylate synthetase.
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Pharmacogenetics of Methotrexate
Response
Several studies have reported the eﬀect of candidate genetic
variants on methotrexate sensitivity. These studies demon-
strate that genetic variants of enzymes and transporters in the
methotrexate pathway, such as methylenetetrahydrofolate reduc-
tase (MTHFR), aminoimidazole carboxamide adenosine ribonu-
cleotide transformylase (ATIC) and ATP-binding cassette trans-
porters (ABCs) are associated with methotrexate response in JIA:
this topic has been reviewed recently (Schmeling et al., 2014).
Our experience on methotrexate pharmacogenetics is related to
the evaluation of the most common functional variants in ATIC,
inosine triphosphate-pyrophosphatase (ITPA) and solute carrier
family 19member 1 (SLC19A1): we selected these candidate vari-
ants on the basis of recent studies evaluating comprehensively
genetic polymorphisms in the methotrexate pharmacokinetic and
pharmacodynamic pathways in patients with JIA and rheuma-
toid arthritis (RAs; Dervieux et al., 2011; Hinks et al., 2011;
Owen et al., 2012). In our analysis (Pastore et al., 2014), the
most common functional variants of ATIC, ITPA, and SLC19A1
were associated with clinical response to methotrexate evalu-
ated as remission stable for a 6-months period, as ACRPed score
and as change in Juvenile Arthritis Disease Score (JADAS) in 69
patients with JIA. ATIC rs2372536 GG genotype was associated
with improved clinical remission (adjusted p-value= 0.0090). For
ITPA, rs1127354 A variant was associated with reduced clinical
remission (adjusted p-value = 0.028). ITPA enzymatic activity,
measured in patients’ erythrocytes, showed that also patients with
wild-type ITPA, but with low ITPA activity, did not respond to
therapy (p-value = 0.0024). SLC19A1 rs1051266 variant showed
an association with worse response in terms of change in JADAS
score after 6 months of therapy (adjusted p = 0.036). The asso-
ciations described in this study about explored genetic variants
and diﬀerent indicators of clinical response are heterogeneous:
this may be secondary to the relatively small number of patients
recruited. The results, therefore, have to be interpreted as prelim-
inary and need further conﬁrmatory studies on larger cohort of
patients.
Diﬀerent studies, including this one, have therefore evaluated
the eﬀects of candidate genetic variants in the complex pathway
of genes involved in methotrexate pharmacokinetics and phar-
macodynamics on response to methotrexate in children with JIA;
however, results are still contrasting and no deﬁnitive genetic
marker of methotrexate response useful for the clinician to tai-
lor therapy of children with JIA has been identiﬁed. This may
be due to the lack of studies considering comprehensively all the
relevant variants, even with an agnostic genome-wide approach
since the mechanism of action of methotrexate in JIA is still
poorly understood, or ﬁne mapping of genetic variants in rele-
vant candidate genes in a suﬃciently powered and prospectively
followed-up patients’ population with standardized protocols,
accounting for all non-genetic potential confounders. Therefore,
more research is needed to fully validate pharmacogenetic mark-
ers for methotrexate response in JIA, considering even the eﬀect
of epigenetic features, such as DNA methylation, as discussed
later in this review.
Recent Pharmacogenomic Studies on
Methotrexate Response in JIA
Genome-wide approaches, using genome-wide DNA scans and
also gene expression arrays or proteomics, can help in under-
standing the genetic contribution to variation in phenotypes
of pharmacological interest, such as response to methotrex-
ate in JIA, by providing a relatively unbiased survey of the
genome to identify previously unrecognized relevant genes.
Indeed, candidate gene approaches have the potential draw-
back that they depend on accurate previous knowledge on the
molecular mechanisms underpinning the phenotype of inter-
est. Genome-wide studies are then particularly useful if lim-
ited knowledge is available on the molecular basis of the phe-
notype of interest. A limitation of genome-wide approaches
is that, given the large number of polymorphisms examined,
many statistically signiﬁcant ﬁndings are false positives (type
I error). Moreover, many platforms available for genome-
wide DNA analysis characterize for each gene just a panel
of SNPs, tag SNPs, selected to be representative of multi-
ple SNPs that are in linkage disequilibrium, therefore the
causative variants are often not directly typed. The large
number of SNPs examined and direct characterization of tag
SNPs only, determines, in genome-wide studies, the need for
large cohorts of patients to identify truly signiﬁcant associa-
tions.
The ﬁrst genome-wide study considering genetic variants for
methotrexate response in JIA was recently published (Cobb et al.,
2014). This study had the overall aim to improve the under-
standing of the variability in response to methotrexate treatment
observed in children with JIA and ultimately deﬁne a multifac-
torial model of response outcomes, involving multiple genetic
variants, and environmental factors. The study was performed by
the CHARMS-JIA GWAS International Consortium and consid-
ered, following stringent quality control for the genomic analysis,
694 JIA cases (from Czech Republic, the Netherlands and UK).
Demographic and clinical variables were collected at baseline
and after 6 months (median 6.2 months, range 4–8 months) of
therapy with methotrexate (median dose 11.3 mg/m2, range 10–
15). Clinical response was evaluated using the ACRPed criteria
with four categories: non-responders (reference category, 31%),
ACRPed30 (8.6%), ACRPed50 (14.6%), and ACRPed70 (45.8%);
association between genotype and response to methotrexate was
analyzed using ordinal regression. Moreover, each of the core-
set variables (erythrocyte sedimentation rate, childhood health
assessment questionnaire, active joint count (AJC), limited joint
count, physician’s global assessment on a visual analog scale
and patient global assessment) determining the ACRPed score
was analyzed individually, using linear regression, recording the
change between baseline, and follow-up. Genotypes were deter-
mined on patients’ DNA using Illumina HumanOmniExpress
Inﬁnium array, which in this study, after appropriate quality
control, allowed genotyping of 586,062 SNPs. In a ﬁrst phase
analysis, some regions were selected by searching for clusters of
associated SNPs (p < 0.001 in at least two of the seven anal-
yses). In a second phase, analysis of these regions was reﬁned,
using SNP imputation to increase density of SNP coverage in
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these regions (imputation was done against the 1000 Genome
Project reference panel of around 37 million SNPs). None of the
potential confounding variables tested (gender, ILAR-JIA sub-
type, center, age at treatment baseline, duration of treatment, time
of treatment, steroid treatment, ethnicity) were associated with
all six individual core-set variables: therefore no adjustment for
these clinical and demographic covariates was done. The ﬁrst
phase analysis identiﬁed 31 genetic regions (p < 0.001). Phase
II analysis, which included additional SNPs in the signiﬁcant
regions, typed by imputation, identiﬁed 14 regions fulﬁlling a
more conservative signiﬁcance threshold (p < 1.0 × 10−5). The
variant rs136855 was the most signiﬁcant (p = 9.81 × 10−8)
within an intron of the calcium channel CACNA1I, associ-
ated with AJC: this gene is implicated in calcium signaling in
neurons and may have other roles that yet have to be dis-
covered, related to methotrexate eﬃcacy. Moreover, a signiﬁ-
cant region included the ABC transporter superfamily member
CFTR/ABCC7, important for drug transport and elimination and
belonging to the same family of ABCC3, known to be involved
in the eﬄux of methotrexate. Finally, two regions (including
variants of ZMIZ1 and TGFI1) showed intriguing functional
overlap with the immune suppressive factor TGF-beta signal-
ing pathway, important for the balance between Th17 and Treg
cells, directly involved in JIA severity, and previously impli-
cated by gene expression proﬁling as relevant for methotrexate
response in JIA (Moncrieﬀe et al., 2010). Although this inter-
esting two-step approach, the study failed to identify an asso-
ciation at a genome-wide level (5 × 10−8) and there is not
a replica on an independent cohort (a very common method
to reduce false positive associations). A previous gene expres-
sion study, performed also by the CHARMS-JIA research group,
applied transcriptome analysis to identify novel pathways/genes
altered by methotrexate in JIA patients and potentially useful
for therapy personalization. Gene expression proﬁling before
and after methotrexate treatment was performed on 11 chil-
dren with JIA, evaluating response after 6 months of treatment.
Genes displaying the most signiﬁcant changes in gene expres-
sion were selected for SNP genotyping. More than 1000 probesets
were diﬀerentially expressed (fold change >1.7, p < 0.05) after
methotrexate treatment in these patients; analysis focused on
seven patients with full response to methotrexate (ACRPed70),
identiﬁed 1065 diﬀerentially expressed probes; after correction
for multiple testing, 87 probe sets in 62 genes resulted as
highly diﬀerentially expressed. Among these, selection for fur-
ther analysis by genotyping was done on six genes selected
on the basis of the level of fold change and potential biologi-
cal relevance. Metastasis-associated lung adenocarcinoma tran-
script 1, upregulated in cells treated by several chemotherapeutic
drugs including methotrexate, displayed the highest fold-change
(12.8, p-value corrected for multiple changes = 0.004) after
methotrexate treatment in patients with JIA. Moreover, zinc ﬁn-
ger enhancer protein 1 (ZEB1), also known as transcription
factor 8 (TCF8), which enhances signaling of TGF-beta was dif-
ferentially expressed after methotrexate treatment (fold change
5.3, p-value = 0.014). The relevance of TGF-beta signaling on
methotrexate response was therefore identiﬁed by two studies
with an agnostic approach, initially considering gene-expression
and then by genome-wide SNP analysis (Moncrieﬀe et al.,
2010).
Recently, the Trial of Early Aggressive Therapy (TREAT) in
JIA patients, compared 2 therapeutic regimens for initial ther-
apy of newly diagnosed polyarticular JIA, i.e., subcutaneous
methotrexate at a relatively high dose (0.5 mg/m2/week, max
40 mg/m2/week) vs. a combination of subcutaneous methotrex-
ate (same dose as other arm), etanercept and oral prednisolone.
The TREAT study also comprised agnostic gene expression stud-
ies, to determine whether RNA proﬁles measured in peripheral
whole blood, by Illumina WG-6 v3, or Illumina HT-12 v4 human
whole genome microarrays, could be used to determine the ther-
apeutic outcome. Results obtained showed that the prognosis
at 6 months in terms of clinically inactive disease was strongly
associated with gene expression at presentation, irrespective of
treatment with methotrexate alone or with the more intense
combination of methotrexate, TNF-alpha inhibitors and gluco-
corticoids. While the models developed in this study were not
statistically robust, given the relatively small number of patients
considered (n = 44), these data support the existence of a
genomic component to prognosis for patients with JIA, that
may be independent from treatment with methotrexate or more
aggressive combinations. At this stage, the authors do not pro-
vide details on genes associated in their study with prognosis:
further studies in larger patient’s populations are needed (Jiang
et al., 2014).
These genome-wide studies with an agnostic proﬁle suggest
that multiple genes determine methotrexate eﬃcacy in JIA, and
not only those involved in methotrexate pharmacokinetics and
pharmacodynamics. Novel pathways and mechanisms therefore
may be relevant to elucidate methotrexate eﬃcacy. If validated
by future targeted replication studies, these novel variants could
improve previously developed methotrexate eﬃcacy predictions
model in JIA. These genome-wide studies did not replicate can-
didate genes studies, since they characterize the contribution of
a diﬀerent type of genetic variation: indeed, in the genome-wide
array used for the SNP analysis, most functional variants, such
as the common SNPs in ATIC, ITPA, and SLC19A1 analyzed
in our study, are not directly typed and the tag SNPs geno-
typed may have an indirect eﬀect too diluted to be evident with
the sample size considered. The variants identiﬁed as signiﬁcant
in this study, however, shed light on previously unrecognized
relevant biological mechanisms to predict methotrexate eﬃcacy
in JIA.
While there is a paucity of GWAS data on MTX response
in JIA, various studies have been published in the context of
other subtypes of RAs or other conditions, considering the eﬀect
the MTX alone or in association with other medications (Wang
et al., 2013; Senapati et al., 2014). In a recent paper, Senapati
et al. (2014) reported genome-wide genotyping data for 457 RA
patients, 297 good and 160 poor responders on MTX monother-
apy. Ten novel suggestive loci were associated with poor response
to methotrexate; interestingly, the associations of published can-
didate genes, namely DHFR (P = 0.014), FPGS (P = 0.035), and
TYMS (P = 0.005) and purine and nucleotide metabolism path-
ways, were conﬁrmed, even if not signiﬁcant at genome-wide
level (Senapati et al., 2014).
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Further Steps
Advancement in sequencing technology now allows deep
sequencing of a panel of candidate genes in a reasonable time
and with acceptable costs. Moreover the development of spe-
ciﬁc algorithms (i.e., Polyphen-2, MutationTaster, SIFT) has
greatly improved the possibility of evaluating the functional
impact of novel genetic variants observed in these studies. Recent
studies have shown that evaluation of rare variants is particu-
larly important to properly predict the phenotype of interest,
such as methotrexate pharmacokinetics and response (Ramsey
et al., 2012): from deep resequencing of methotrexate transporter
SLCO1B1 exons in 699 children, the authors identiﬁed 93 SNPs,
15 of which were non-synonymous (NS). Three of these NS
SNPs were common, with a minor allele frequency (MAF) >5%,
one had low frequency (MAF 1%–5%), and 11 were rare (MAF
<1%). NS SNPs (common or rare) predicted to be functionally
damaging were more likely to be found among patients with
the lowest methotrexate clearance than patients with high clear-
ance. SLCO1B1 variants accounted for 10.7% of the population
variability in clearance. Of that variability, common NS variants
accounted for the majority, but rare damaging NS variants con-
stituted 17.8% of SLCO1B1’s eﬀects (1.9% of total variation) and
had larger eﬀect sizes than common NS variants.
Besides evaluation of DNA sequence or mRNA proﬁles, other
elements of genetic variants may be related to drug eﬀects: epige-
netic features, such DNA methylation or microRNA expression
proﬁles, inﬂuence drug response (Ivanov et al., 2014) and anal-
ysis of their eﬀects on clinical response is completely missing in
patients with JIA treated with methotrexate.
The concentration of methotrexate polyglutamates (MTX-
PG) in patients’ erythrocytes has been proposed as a marker of
eﬃcacy of treatment with methotrexate in patients with rheuma-
tologic diseases: levels of MTX-PG metabolites are higher in
patients who respond to therapy; however, some studies report
conﬂicting results. Data currently available in the literature on
the usefulness of the measurement of MTX-PG metabolites
in patients with JIA is limited and the value of these tests
in predicting clinical response is still unclear (Stocco et al.,
2012). An association between MTX-PG levels and response
to therapy has been recently conﬁrmed in the ﬁrst prospective
study in JIA (C´alasan et al., 2015). One hundred and thir-
teen JIA patients were followed from methotrexate start until
12 months. Erythrocyte MTX-PG with 1–5 glutamate residues
were measured at 3 months with tandem mass spectrometry.
The clinical outcomes considered were JADAS and incidence
of adverse eﬀects. Median JADAS decreased from 12.7 (inter-
quartile range, IQR: 7.8–18.2) at baseline to 2.9 (IQR: 0.1–
6.5) at 12 months. Higher concentrations of MTX-PG3, MTX-
PG4, MTX-PG5, and MTX-PG3-5 were associated with lower
disease activity at 3 months and over 1 year. No signiﬁcant
association was detected between MTX-PG concentration and
incidence of adverse eﬀects (methotrexate intolerance, hepato-
toxicity and bone marrow suppression). Therefore, erythrocyte
MTX-PGs are associated with lower JADAS at 3 months and
during 1 year of methotrexate treatment and could be a plausi-
ble candidate for therapeutic drug monitoring of methotrexate
in JIA. Genomic variants associated with MTX−PG have been
reported in children with acute lymphoblastic leukemia (French
et al., 2009), even if these studies are still missing in patients
with JIA.
Further studies will establish innovative integrated pharma-
cogenomic and pharmacokinetic features important to identify
patients that will respond to methotrexate, a safe and cost-
eﬀective agent that remains the ﬁrst-line therapy of JIA for active
and persistent arthritis, in comparison to other more expensive
and less safe treatments. Application of pharmacologically guided
treatment of JIA will allow rationalization and reduction of costs
associated with care, by directing and personalizing the use of
methotrexate.
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